RxDoctor Payments Data

Ankur Khosla, MD

Interventional Pain Medicine · Shenandoah, TXNPI 1861760985

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (32.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Abbott at 28.5% of the total. 2025 is the largest year on record at $69,467, more than ten times the $5,938 reported in 2019. Among interventional pain medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$277,076in general payments, 2019–2025

Across 1,034 payments — averaging $267.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$79K
  • Surgentec$71K
  • Spinal Simplicity, LLC$54K
  • Averitas Pharma Inc.$31K
  • Boston Scientific$19K
  • Painteq LLC$4K
  • plus $19K from 36 others
$233,998in ownership & investment interests, 2019–2025

Across 6 payments — averaging $39,000 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spinal Simplicity, LLC$234K

What the payments were for

  • Royalty or licence$30,72611%
  • Consulting fees$90,25433%
  • Speaking & faculty fees$78,96829%
  • Travel & lodging$39,36014%
  • Food & beverage$31,54211%
  • Education$6,1492%
  • Entertainment$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,076 in reported general payments places this provider in the 95th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,181,484
Medicare patients
553
Services billed
52,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium38$61,478
Cephalexin226$4,689
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen297$2,939
Tizanidine Hcl420$1,514
Gabapentin176$1,350
Diclofenac Sodium22$341
Cyclobenzaprine Hcl42$213
Clindamycin Hcl12$88
Tramadol Hcl17$84
Meloxicam39$83
Methylprednisolone12$67

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →